Vind-M 50mg/500mg 50mg/850mg 50mg/1000mg Tablets [Vildagliptin/Metformin HCI]



DESCRIPTION:

Wind-M Vildaglightin/Medformin HCI) combines two antihyperglycemic agents to improve glycemic control in gatients with type 2 disbetes, Vildaglightin and Medformin HCI. Vildaglightin is an inhibitor of the enzyme dispetitydeptidate 4 (DPP-Al) which plays are lot in regulating insulins servicton, Medformin HCI is a member of the biguanide class and not chemically or pharmacologically related to any other classes of oral

antihyperglycemic agents. QUALITATIVE AND QUANTITATIVE COMPOSITION:

Sach him coated tablet contains:

Lach him coated tablet used the coated tablet to contains:

Lach him coated tablet used the coated tablet to t

hours, with a passive summer.

John Burnston State Sta

THERAPUTIC INJECTIONS IN THE ADMINISTRATION OF THE ADMINISTRATION

In triple combination with insulin, when the state of the patients and adequate pleyenic control.

DOSAGE AND ADMINISTRATION:

DOSAGE AND ADMINISTRATION:

The disce of anthreps playeame therapy with Vime4M should be individualized on the basis of the patient's current regimen, effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100mg wildingships. Based on the patient's current ose of videgiption and/or mentorinin HCI, Vime4M may be intitated at either the Soning ScOmp. SO mg ScOmp or SOng 1200mg tablet strength twice daily one will be some strength of the soning ScOmp. SO mg ScOmp or SOng 1200mg tablet strength twice daily one so the soning scome of the soning ScOmp. SO mg ScOmp or SOng 1200mg tablet strength twice daily one so the soning scome of the soning

Indications	Starting Dose
Patients inadequately controlled on metformin HCI monotherapy	Vidagliptin as 50mg twice daily plus the dose of metformin HCI already being taken

Patients switching from co-administration of Vidagliptin and metformin HCI as separate tablets

Patients inadequately controlled on dual combination with Metformin HCl and a Sulfonylurea

Patients inadequately controlled on dual combination therapy with Insulin and the maximal tolerated dose of

Metformin HCI 1 taken

* When vildagliptin/metformin HCI is used in combination with a sulphomylurea, a lower dose of
the sulphonylurea may be considered to reduce the risk of hypoglycemia.

Special Population:
Hepatic Impairment: Vimd-M should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >

Initiated at the dose of Vildaglintin and Metformin HCI

Vildagliptin as 50mg twice daily plus the dose of metformin already being

ready being taker Vildagliptin as 50mg twice daily plus the dose of metformin already being

patients with pre-treatment alanine aminotransterase (ALT) or aspartate aminotransterase (AST) > 3 times the upper limit of normal (ULN). Renal Impairment: Vimd-M should not be used in patients with creatinine clearance <60ml/min. Elderly (> 65 years): Elderly patients taking Vimd-M should have their renal function monitored regularly CONTRAINDICATIONS:

Commerce and adolescents (< 18 years).

PRECAUTIONS:

WARNING: LACTIC ACIDOSIS: Lactic acidosis is a rare, but serious complication that can occur due to meformin accumilation. The risk increases with conditions such as sepsis, depringration, access acidotil intake, hepatic hydrogeneous accumilation. The risk increases with conditions such as sepsis, depringration, access acidotil intake, hepatic hydrogeneous properties and consideration of the conditions and the patient into the conditions are properties, and consideration and conditions are properties, and access acidotic acidoti

before the country of the country of

- Myedipme increases absorption, Cmax and AU. Of metrorimi, and increases excretion of metrorimal, and increases excretion of metrorimal, and increases excretion in a confidence of the monitoring and dose adjustment of Vimbeh And/or cottoin drugs e.g., amiloride, digoxin, morphine, procalinamide, quinidine, quinine, rantidine, triameterne, trimethorprim, or vancompricin that are excreted via the provimal renar lubular secretory system is recommended. - Thicardes & other diuretic, corticosteroids, phenothinatines, thyroid drugs, estrogens, oral contraceptives, phenytoin, incident lead, sympathominetics, colclum channel blocking drugs and isonizated produce hyperglycaemia. Patient should be closely observed to maintain adequate glycemic ADVERSE REACTIONS:
Common: Hypoglycemia, temor, headache, dizziness, nausea, hyperhidrosis, chills, GERDS. Uncommon: Faigleu, clairreba & Ritualdence.
OVERDOSAGE:
In the event of an overdose initiate supportive therapy. Haemodialysis may be considered to remove haemodialysis more designation of the removed by haemodialysis.

INSTRUCTIONS:
- Store below 30°C.
- Protect from light & moisture.
- Keep out of reach of children.
To be sold on prescription of a registered medical practitio

HOW SUPPLIED: Vimd-M Tablets 50mg/500mg is available in pack of 14's. Vimd-M Tablets 50mg/850mg is available in pack of 14's. Vimd-M Tablets 50mg/1000mg is available in pack of 14's.

خوراک : 13 کشر کی جایت کے مطابق استعمال کریں۔ جامب : دہا کہ ''انڈ کر کے ''نگی کریئے ہے کہ دوجرائرات پر کئیں۔ دو تی اور کی ہے تاکہ '' بچل ل کا کائی ہے دور کئیں۔ صرف پر شواؤ اکثر کے کئے کہ مطابق فروٹ کریں۔



SIGMA Manfactured By:
SIGMA PHARMA (International Private Limited.)
PHARMA E50 North Western Industrial Zone
Port Qasim Authority, Karachi-Pakistan
www.sigmapharma.com.pk